Summary:
Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at Visage Dermatology LLC on 08/12/2026. The laboratory was surveyed under 42 CFR Part 493 CLIA requirements. Standard deficiencies cited are as follows: D5601 HISTOPATHOLOGY CFR(s): 493.1273(a)(f) (a) As specified in 493.1256(e)(3), fluorescent and immunohistochemical stains must be checked for positive and negative reactivity each time of use. For all other differential or special stains, a control slide of known reactivity must be stained with each patient slide or group of patient slides. Reactions of the control slide with each special stain must be documented. This STANDARD is not met as evidenced by: Based on record review and interview, the laboratory failed to document hematoxylin and eosin stained control slides were acceptable for eight of thirteen days selected for reviiew for the subspeicality of Histopathology. Findings included: 1. The laboratories policy and procedure manual, signed by the Lab Director 10/21/2025 was reviewed. The physician reading hematoxyline and eosin stained slides were to initial the quality control form each day of testing, attesting that the quality control slide was acceptable. 2. Mohs Quality Control Worksheets were reviewed. Stained control slides were created for; 07/01, 07/06, 07/16, 07/20, and 07/30/2025, for 12/5, 12/19, and 12/29/2025, and for 04/06, 04/10, 04/13, 04/24, and 04/27/2026 for a total of thirteen days. There was no indication by the interpreting physician that slides were acceptable on 12/05, 12/19, 12/29/2025, 04/06, 04/10, 04/13, 04/24, or o4/27/2026. 3. An interview was conducted with the Clinical Manager on 08/12/2026 at approximately 1:50 p.m. They confirmed the above data. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --